Research programme: anticancer and anti-inflammation antibodies - MorphoSys
Latest Information Update: 16 Jul 2016
At a glance
- Originator MorphoSys
- Class Antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Germany (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 19 Jan 2009 Early research in Inflammation in Germany (Parenteral)